BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Study to Evaluate Efficacy and Long-term Safety of Oral Ozanimod in Chinese Participants With Moderately to Severely Active Ulcerative Colitis (UC)

Phase 3

Terminated

Conditions: Ulcerative Colitis

Interventions: Drug: Placebo
Drug: Ozanimod

First Posted Date: 2022-12-09

Last Posted Date: 2025-03-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 131

Registration Number: NCT05644665

Locations: 🇨🇳
Local Institution - 0012, Hefei, Anhui, China
🇨🇳
Local Institution - 0013, Wuhu, Anhui, China
🇨🇳
Local Institution - 0052, Beijing, Beijing, China

and more 48 locations

A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: Cendakimab

First Posted Date: 2022-12-06

Last Posted Date: 2023-08-01

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT05638282

Locations: 🇨🇳
Local Institution - 0001, Guangzhou, Guangdong, China

A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in Japan

Recruiting

Conditions: Psoriasis

First Posted Date: 2022-12-01

Last Posted Date: 2024-06-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 300

Registration Number: NCT05633264

Locations: 🇯🇵
EP Pharmaline, Tosima-ku, Tokyo, Japan

A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma

Phase 3

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Nivolumab + Relatlimab
Drug: rHuPH20

First Posted Date: 2022-11-22

Last Posted Date: 2025-03-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 570

Registration Number: NCT05625399

Locations: 🇪🇸
Local Institution - 0086, A Coruna, Spain
🇪🇸
Local Institution - 0134, Badalona, Spain
🇪🇸
Local Institution - 0047, Barcelona, Spain

and more 146 locations

A Study of BMS-986360/CC-90001 Alone and in Combination With Chemotherapy or Nivolumab in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumors

Interventions: Drug: BMS-986360
Drug: Docetaxel
Drug: Nivolumab
Drug: Capecitabine

First Posted Date: 2022-11-22

Last Posted Date: 2025-05-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 220

Registration Number: NCT05625412

Locations: 🇺🇸
Local Institution - 0046, West Valley City, Utah, United States
🇺🇸
Local Institution - 0029, Los Angeles, California, United States
🇺🇸
Local Institution - 0051, Los Angeles, California, United States

and more 32 locations

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Deucravacitinib
Other: Placebo

First Posted Date: 2022-11-17

Last Posted Date: 2025-05-18

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 490

Registration Number: NCT05620407

Locations: 🇵🇪
Local Institution - 0100, Lima, Peru
🇺🇸
UCSD - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States
🇺🇸
East Bay Rheumatology Medical Group, Inc, San Leandro, California, United States

and more 196 locations

A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

Phase 3

Recruiting

Conditions: Systemic Lupus Erythematosus

Interventions: Other: Placebo
Drug: Deucravacitinib

First Posted Date: 2022-11-15

Last Posted Date: 2025-05-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 490

Registration Number: NCT05617677

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Local Institution - 0229, Phoenix, Arizona, United States
🇺🇸
Local Institution - 0230, Phoenix, Arizona, United States

and more 207 locations

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Neoplasms, Ovarian

Interventions: Drug: MORAb-202
Drug: Paclitaxel
Drug: Pegylated Liposomal Doxorubicin (PLD)
Drug: Topotecan

First Posted Date: 2022-11-14

Last Posted Date: 2025-03-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 90

Registration Number: NCT05613088

Locations: 🇺🇸
Local Institution - 0065, Sacramento, California, United States
🇺🇸
Local Institution - 0025, San Francisco, California, United States
🇺🇸
Local Institution - 0061, Columbus, Ohio, United States

and more 47 locations

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: Methotrexate
Drug: Rosuvastatin
Drug: Metformin
Dietary Supplement: Glucose
Drug: Leucovorin

First Posted Date: 2022-11-14

Last Posted Date: 2024-03-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 76

Registration Number: NCT05615012

Locations: 🇺🇸
Local Institution - 0001, Miami, Florida, United States

A Post-Authorization, Long-term Study of Ozanimod Real-world Safety

Active, not recruiting

Conditions: Multiple Sclerosis, Relapsing-Remitting

First Posted Date: 2022-11-04

Last Posted Date: 2022-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9000

Registration Number: NCT05605782

Locations: 🇺🇸
Evidera, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy